The Journal of Allergy and Clinical Immunology
Volume 116, Issue 1 , Pages 65-72 , July 2005

Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle

  • Bill T. Ameredes, PhD

      Affiliations

    • Corresponding Author InformationReprint requests: Bill T. Ameredes, PhD, Research Assistant Professor of Medicine, Asthma, Allergy, and Airway Research Center, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, 628NW Montefiore University Hospital, 3459 Fifth Ave, Pittsburgh, PA 15213.
    • ,
  • William J. Calhoun, MD

Received 15 June 2004 ,Revised 1 March 2005 ,Accepted 7 March 2005.

References 

  1. Saunders MA, Mitchell JA, Seldon PM, Yacoub MH, Barnes PJ, Giembycz MA, et al. Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone. Br J Pharmacol. 1997;120:545–546
  2. Endo T, Uchida Y, Nomura A, Ninomiya H, Ohse H, Saotome M, et al. Activated eosinophils stimulate endothelin-1 release from airway epithelial cells by direct adherence via adhesion molecules. Pulm Pharmacol Ther. 1997;10:81–87
  3. Hallsworth MP, Soh CP, Twort CH, Lee TH, Hirst SJ. Cultured airway smooth muscle cells stimulated by interleukin-1 beta enhance eosinophil survival. Am J Respir Cell Mol Biol. 1998;19:910–919
  4. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033–1039
  5. Broide DH, Lotz M, Cuomo AJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992;89:958–967
  6. Hallsworth MP, Moir LM, Lai D, Hirst SJ. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med. 2001;164:688–697
  7. Farmer P, Pugin J. β-adrenergic agonists exert their “anti-inflammatory” effects in monocytes cells through the IκB/NF-κB pathway. Am J Physiol Lung Cell Mol Physiol. 2000;279:L675–L682
  8. Taylor DR, Sears MR, Herbison GP, Flannery EM, Print CG, Lake DC, et al. Regular inhaled beta agonists in asthma: effects on exacerbations and lung function. Thorax. 1993;48:134–138
  9. Sears MR, Taylor DR. The beta 2-agonist controversy. Drug Saf. 1994;11:259–283
  10. Handley D. The asthma-like pharmacology and toxicology of the (S)-isomers of beta-agonists. J Allergy Clin Immunol. 1999;104:S69–S76
  11. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943–952
  12. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2adrenergic receptors. Clin Rev Allergy Immunol. 1996;14:37–45
  13. Hartley D, Middlemiss D. Absolute configuration of the optical isomers of salbutamol. J Med Chem. 1971;14:7–36
  14. Izeboud CA, Vemeulen RM, Zwart A, Voss H-P, van Miert AS, Witkamp RF. Stereoselectivity at the β2-adrenoceptor on macrophages is a major determinant of the anti-inflammatory effects of β2-agonists. Naunyn Schmiedebergs Arch Pharmacol. 2000;362:184–189
  15. Mazzoni L, Naef R, Chapman ID, Morley J. Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta-2-selective sympathomimetics. Pulm Pharmacol. 1994;7:367–376
  16. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998;53:347–354
  17. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol. 1998;38:1096–1106
  18. Panettieri RA, Murray RK, DePalo LR, Yadvish PA, Kotlikoff MI. A human airway smooth muscle cell line that retains physiological responsiveness. Am J Physiol. 1989;256(2 Pt. 1):C329–C335
  19. Hirst SJ. Airway smooth muscle cell culture: application to studies of airway wall remodeling and phenotype plasticity in asthma. Eur Respir J. 1996;9:808–820
  20. Gerthoffer WT, Singer CA. MAPK regulation of gene expression in airway smooth muscle. Respir Physiol Neurobiol. 2003;137:237–250
  21. Lazzeri N, Belvisi MG, Patel HJ, Yacoub MH, Chung FK, Mitchell JA. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells: relevance to therapy. Am J Respir Cell Mol Biol. 2001;24:44–48
  22. Kerrebijn KF. Long-term drug treatment of asthma in children. Lung. 1990;168(suppl):142–153
  23. Newman SP. Therapeutic aerosols. In:  Clarke SW,  Pavia D editor. Aerosols and the lung in clinical and experimental aspects. London: Butterworths; 1984;p. 197–224
  24. Sleigh MA, Blake JR, Liron N. The propulsion of mucus by cilia. Am Rev Respir Dis. 1988;137:726–741
  25. Atabai K, Ware LB, Snider ME, Koch P, Daniel B, Nuckton TJ, et al. Aerosolized beta(2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med. 2002;28:705–711
  26. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Cell Mol Biol. 1999;160:1136–1141
  27. Roth M, Johnson PRA, Rüdiger JJ, King GG, Ge Q, Burgess JK, et al. Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronized cellular signaling. Lancet. 2002;360:1293–1299
  28. Baker JG, Hall IP, Hill SJ. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol. 2003;64:1357–1369
  29. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol. 1999;55:50–57
  30. Kleinert H, Euchenhofer C, Ihrig-Biedert I, Forstermann U. Glucocorticoids inhibit induction of nitric oxide synthase II by downregulating cytokine-induced activity of transcription factor nuclear factor kappa B. Mol Pharmacol. 1996;49:15–21
  31. Umino T, Hangjun Zhu WY, Liu X, Manouilova LS, Spurzem JR, Leuschen MP, et al. Modification of type I collagenous gels by alveolar epithelial cells. Am J Respir Cell Mol Biol. 2000;22:702–707
  32. Elias JA, Yang W, Zheng T, Panettieri R. Cytokine- and virus-stimulated airway smooth muscle cells produce IL-11 and other IL-6-type cytokines. Am J Physiol. 1997;273(3 Pt. 1):L648–L655
  33. Pascual RM, Billington CK, Hall IP, Panettieri RA, Fish JE, Peters SP, et al. Mechanisms of cytokine effects on G-protein-coupled receptor-mediated signaling in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1425–L1435
  34. Shore SA, Moore PE. Regulation of β-adrenergic responses in airway smooth muscle. Respir Physiol Neurobiol. 2003;137:179–195
  35. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoreceptor agonist bronchodilator. Life Sci. 1993;52:2145–2160
  36. Thomlinson PR, Wilson JW, Stewart AG. Salbutamol inhibits the proliferation of human airway smooth muscle cells grown in culture: relationship to elevated cAMP levels. Biochem Pharmacol. 1995;49:1809–1819
  37. Ye RD. β-Adrenergic agonists regulate NF-κB activation through multiple mechanisms. Am J Physiol Lung Cell Mol Physiol. 2000;279:L615–L617
  38. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol. 2001;124:478–484
  39. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)- isomers of albuterol: anti-inflammatory influences of (R)- isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol. 2002;109:449–454
  40. Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, et al. Biological actions of formoterol isomers. Pulm Pharmacol Ther. 2002;15:135–145
  41. Agrawal DK, Ariyarathna K, Kelbe PW. (S)-albuterol activate pro-constrictatory and pro-inflammatory pathways in human bronchial smooth muscle cells. J Allergy Clin Immunol. 2004;113:503–510
  42. Zhang XY, Zhu FX, Olszewski MA, Robinson NE. Effects of enantiomers of beta 2-agonists on ACh release and smooth muscle contraction in the trachea. Am J Physiol. 1998;274:L32–L38
  43. Milligan G, Bond RA. Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci. 1997;18:468–474
  44. Chidiac HP, Valiquette TE, Dennis M, Bouvier M. Inverse agonist activity of β-adrenergic agonists. Mol Pharmacol. 1994;45:490–499
  45. Daaka Y, Luttrell LM, Lefkowittz RJ. Switching of the coupling of the β-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;370:88–91
  46. Stevens PA, Milligan G. Efficacy of inverse agonists in cells overexpressing a constitutively active beta2-adrenoceptor and type II adenylyl cyclase. Br J Pharmacol. 1998;123:335–343
  47. Volcheck GW, Gleich GJ, Kita H. Pro- and anti-inflammatory effects of beta-adrenergic agonists on eosinophil response to IL-5. [abstract] J Allergy Clin Immunol. 1998;101:S35
  48. National Asthma Education and Prevention Program. Expert Panel report II: guidelines for the diagnosis and treatment of asthma. Bethesda (MD): National Institutes of Health; 1997;
  49. Currie GP, Stenback S, Lipworth BJ. Effects of fluticasone vs. fluticasone/salmeterol on airway caliber and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol. 2003;56:11–17
  50. Nelson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med. 1998;157:184–191

 Supported by the American Respiratory Alliance of Western Pennsylvania and Sepracor, Inc.Disclosure of potential conflict of interest: Bill Ameredes and William Calhoun have consultant arrangements with Sepracor, Inc, receive grant/research support from Sepracor, Inc, and are on the speakers' bureau for Sepracor, Inc.

PII: S0091-6749(05)00526-9

doi: 10.1016/j.jaci.2005.03.007

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 1 , Pages 65-72 , July 2005

Article Tools

* Image Usage & Resolution